112 related articles for article (PubMed ID: 38504071)
41. Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors.
Akagi K; Oki E; Taniguchi H; Nakatani K; Aoki D; Kuwata T; Yoshino T
Cancer Sci; 2021 Mar; 112(3):1105-1113. PubMed ID: 33403729
[TBL] [Abstract][Full Text] [Related]
42. Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer.
Yamashita K; Iwatsuki M; Yasuda-Yoshihara N; Morinaga T; Nakao Y; Harada K; Eto K; Kurashige J; Hiyoshi Y; Ishimoto T; Nagai Y; Iwagami S; Baba Y; Miyamoto Y; Yoshida N; Ajani JA; Baba H
Br J Cancer; 2021 Feb; 124(3):595-603. PubMed ID: 33100329
[TBL] [Abstract][Full Text] [Related]
43. Gastric cancer.
Smyth EC; Nilsson M; Grabsch HI; van Grieken NC; Lordick F
Lancet; 2020 Aug; 396(10251):635-648. PubMed ID: 32861308
[TBL] [Abstract][Full Text] [Related]
44. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors.
Galluzzi L; Humeau J; Buqué A; Zitvogel L; Kroemer G
Nat Rev Clin Oncol; 2020 Dec; 17(12):725-741. PubMed ID: 32760014
[TBL] [Abstract][Full Text] [Related]
45. Survival analysis in gastric cancer: a multi-center study among Iranian patients.
Talebi A; Mohammadnejad A; Akbari A; Pourhoseingholi MA; Doosti H; Moghimi-Dehkordi B; Agah S; Bahardoust M
BMC Surg; 2020 Jul; 20(1):152. PubMed ID: 32660458
[TBL] [Abstract][Full Text] [Related]
46. Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment.
Sato H; Okonogi N; Nakano T
Int J Clin Oncol; 2020 May; 25(5):801-809. PubMed ID: 32246277
[TBL] [Abstract][Full Text] [Related]
47. VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study.
Smyth E; Knödler M; Giraut A; Mauer M; Nilsson M; Van Grieken N; Wagner AD; Moehler M; Lordick F
Front Oncol; 2019; 9():1320. PubMed ID: 32083013
[No Abstract] [Full Text] [Related]
48. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Marabelle A; Le DT; Ascierto PA; Di Giacomo AM; De Jesus-Acosta A; Delord JP; Geva R; Gottfried M; Penel N; Hansen AR; Piha-Paul SA; Doi T; Gao B; Chung HC; Lopez-Martin J; Bang YJ; Frommer RS; Shah M; Ghori R; Joe AK; Pruitt SK; Diaz LA
J Clin Oncol; 2020 Jan; 38(1):1-10. PubMed ID: 31682550
[TBL] [Abstract][Full Text] [Related]
49. Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients.
Duffy MJ; Crown J
Clin Chem; 2019 Oct; 65(10):1228-1238. PubMed ID: 31315901
[TBL] [Abstract][Full Text] [Related]
50. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
[TBL] [Abstract][Full Text] [Related]
51. Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions.
Petrillo A; Pompella L; Tirino G; Pappalardo A; Laterza MM; Caterino M; Orditura M; Ciardiello F; Lieto E; Galizia G; Castoro C; De Vita F
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30901943
[TBL] [Abstract][Full Text] [Related]
52. What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives.
Tirino G; Pompella L; Petrillo A; Laterza MM; Pappalardo A; Caterino M; Orditura M; Ciardiello F; Galizia G; De Vita F
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30205505
[TBL] [Abstract][Full Text] [Related]
53. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.
Bang YJ; Ruiz EY; Van Cutsem E; Lee KW; Wyrwicz L; Schenker M; Alsina M; Ryu MH; Chung HC; Evesque L; Al-Batran SE; Park SH; Lichinitser M; Boku N; Moehler MH; Hong J; Xiong H; Hallwachs R; Conti I; Taieb J
Ann Oncol; 2018 Oct; 29(10):2052-2060. PubMed ID: 30052729
[TBL] [Abstract][Full Text] [Related]
54. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.
Fuchs CS; Doi T; Jang RW; Muro K; Satoh T; Machado M; Sun W; Jalal SI; Shah MA; Metges JP; Garrido M; Golan T; Mandala M; Wainberg ZA; Catenacci DV; Ohtsu A; Shitara K; Geva R; Bleeker J; Ko AH; Ku G; Philip P; Enzinger PC; Bang YJ; Levitan D; Wang J; Rosales M; Dalal RP; Yoon HH
JAMA Oncol; 2018 May; 4(5):e180013. PubMed ID: 29543932
[TBL] [Abstract][Full Text] [Related]
55. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy.
Li K; Tian H
J Drug Target; 2019 Mar; 27(3):244-256. PubMed ID: 29448849
[TBL] [Abstract][Full Text] [Related]
56. Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis.
Li Z; Shan F; Wang Y; Zhang Y; Zhang L; Li S; Jia Y; Xue K; Miao R; Li Z; Ji J
PLoS One; 2018; 13(1):e0189294. PubMed ID: 29370182
[TBL] [Abstract][Full Text] [Related]
57. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK; Boku N; Satoh T; Ryu MH; Chao Y; Kato K; Chung HC; Chen JS; Muro K; Kang WK; Yeh KH; Yoshikawa T; Oh SC; Bai LY; Tamura T; Lee KW; Hamamoto Y; Kim JG; Chin K; Oh DY; Minashi K; Cho JY; Tsuda M; Chen LT
Lancet; 2017 Dec; 390(10111):2461-2471. PubMed ID: 28993052
[TBL] [Abstract][Full Text] [Related]
58. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming.
Tian L; Goldstein A; Wang H; Ching Lo H; Sun Kim I; Welte T; Sheng K; Dobrolecki LE; Zhang X; Putluri N; Phung TL; Mani SA; Stossi F; Sreekumar A; Mancini MA; Decker WK; Zong C; Lewis MT; Zhang XH
Nature; 2017 Apr; 544(7649):250-254. PubMed ID: 28371798
[TBL] [Abstract][Full Text] [Related]
59. Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease.
Liu J; Blake SJ; Yong MC; Harjunpää H; Ngiow SF; Takeda K; Young A; O'Donnell JS; Allen S; Smyth MJ; Teng MW
Cancer Discov; 2016 Dec; 6(12):1382-1399. PubMed ID: 27663893
[TBL] [Abstract][Full Text] [Related]
60. HER2 Status in Gastric and Gastroesophageal Junction Cancer: Results of the Large, Multinational HER-EAGLE Study.
Kim WH; Gomez-Izquierdo L; Vilardell F; Chu KM; Soucy G; Dos Santos LV; Monges G; Viale G; Brito MJ; Osborne S; Noé J; Du X
Appl Immunohistochem Mol Morphol; 2018 Apr; 26(4):239-245. PubMed ID: 27490762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
